This research will develop rational approaches to the design and synthesis of inhibitors of the aspartyl protease from the feline immunodeficiency virus (FIV) and from the human immunodeficiency virus (HIV-1). It will focus on the following programs: 1. Develop effective and high-affinity small peptide substrates containing a scissle Tyr-Pro bond based on the sequences around the cleavage sites of FIV protease. 2. Investigate the mechanism of FIV protease reaction with synthetic substrates. 3. Design and synthesize Tyr-Pro peptide isostere and transition state analog inhibitors, or mechanism-based inactivators based on its cleavage reaction catalyzed by FIV and HIV protease. 4. Use computer-assisted and mechanism-based rational drug design cycles to improve the potency of inhibitors; incorporate additional peptide or nonpeptide complementarity components to the inhibitors. 5. Develop new chemistry for the synthesis of protease inhibitors in general and aspartyl proteases in particular. Significant contributions in the areas of biomedicine, drug design, and synthetic organic chemistry are expected. These developments will facilitate the discovery and development of new therapeutic agents for AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM048870-07
Application #
6107670
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Morris, Garrett M; Green, Luke G; Radi?, Zoran et al. (2013) Automated docking with protein flexibility in the design of femtomolar ""click chemistry"" inhibitors of acetylcholinesterase. J Chem Inf Model 53:898-906
Breuer, Sebastian; Sepulveda, Homero; Chen, Yu et al. (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50:4371-81
Chang, Max W; Torbett, Bruce E (2011) Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol 410:756-60
Chang, Max W; Giffin, Michael J; Muller, Rolf et al. (2010) Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J 429:527-32
Chang, Max W; Ayeni, Christian; Breuer, Sebastian et al. (2010) Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One 5:e11955
Sundstrom, Magnus; Chatterji, Udayan; Schaffer, Lana et al. (2008) Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology 371:394-404
Nelson, Josh D; Kinkead, Heather; Brunel, Florence M et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377:170-83
Giffin, Michael J; Heaslet, Holly; Brik, Ashraf et al. (2008) A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem 51:6263-70
Huey, Ruth; Morris, Garrett M; Olson, Arthur J et al. (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-52
Heaslet, Holly; Rosenfeld, Robin; Giffin, Mike et al. (2007) Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr 63:866-75

Showing the most recent 10 out of 60 publications